исном Hypertension

in Low and Middle Income Countries

Condition covered

Adults with essential (primary) hypertension

Interventions covered

Pharmacological and non-pharmacological



Details

- Recorded via the Beliefs about Medicine Questionnaire (BMQ [BMQ-Specific section]).
 Includes physical activity (recommended to track via the International Physical Activity Questionnaire [IPAQ-Short Form]), medication adherence (recommended to track via the Hill-Bone Compliance to High Blood Pressure Therapy Scale -South Africa Version [Medication taking sub-scale]) and salt intake (recommended to track via the WHO STEPS Instrument).
- 3 Includes survival (overall and cardiovascular), blood pressure control, hypertensive urgencies and hypertensive emergencies, and erectile function (recommended to track via PROMIS single question),
- 4 Includes hospitalization, peripheral artery disease, hypertensive crisis, heart failure, ischaemic heart disease, cerebrovascular disease, atrial fibrillation, and renal disease
- 5 Recommended to track via one of the following: PROMIS GH-10 v1.2, EQ-5D-3L, WHODAS v2.0, VR-12

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/

© 2023 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more Sets of Patient-Centered Outcome Measures. Version 5.0.1 Revised: January 2023

исном Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsors

UNOVARTIS FOUNDATION

The Working Group



Belarus

Vladislav Podpalov | Belarusian Hypertension Society, Vitebsk State Medical University

Brazil

Otavio Berwanger | Hospital do Coração Celso Amodeo | Brazilian Society of Cardiology

Cameroon

Anastase Dzudie Tamdja | Pan African Society of Cardiology, University of Yaounde

Canada

Norman Campbell | University of Calgary

Ernesto Schiffrin | McGill University, Jewish General Hospital

Ghana

Peter Lamptey | London School of Hygiene and Tropical Medicine, FHI 360

India

Raghupathy Anchala | Indian Institute of Public Health Hyderabad, Public Health Foundation of India

Malaysia

Yook-Chin Chia | University of Malaya, Institute for Healthcare Development at Sunway University, Malaysian Society of Hypertension

Mozambique

Albertino Damasceno | Eduardo Mondlane University

Portugal

Manuela Fiuza | Universidade de Lisboa António Vaz Carneiro | Universidade de Lisboa

Switzerland

Fareed Mirza | Novartis Foundation United Kingdom

Dorothea Nitsch | London School of Hygiene and Tropical Medicine

United States of America

Gbenga Ogedegbe | New York University Langone Medical Center

Vietnam

Nam Phuong Do Thi | Heart Institute of Ho Chi Minh City

* Two patient representatives from Mexico and Tanzania were also members of the Working Group.

Acknowlegements: We would like to thank the following individuals for their valuable contributions to the project: Dr. Kolo Philip Manma | University of Ilorin, Nigeria

Dr. Prajjwal Pyakurel | B.P. Koirala Institute of Health Sciences, Nepal